ArticleSLAS discovery : advancing life sciences R & D2026
Repurposing drug screen for the identification of helicase inhibitors from viruses of pandemic concern.
Article in SLAS discovery : advancing life sciences R & D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Several families of viruses encode helicase enzymes with essential roles in viral genome replication and transcription, including several RNA virus families of pandemic concern, such as coronaviruses and flaviviruses. Viral helicases are widely considered to be promising antiviral targets with some DNA virus helicase inhibitors already approved for clinical use. Here, we demonstrate that the SARS-CoV-2 viral helicase, nsp13, is essential for viral replication. Using a previously developed in vitro helicase dsRNA unwinding assay, we screened 208 repurposed small molecules for nsp13 inhibition. Nine of these small molecules had a half-maximal inhibitory concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.